MilliporeSigma’s New Microbial Bioburden Testing System Offers Enhanced Results and Increased Productivity

Fujifilm Completes Expansion of Cell Therapy Facility

With FDA's clearance, Kedrion can manufacture Ryplazim (plasminogen, human-tvmh), the first and only FDA-approved therapy for treating PLGD-1, at its Bolognana, Italy, site.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Pii Invests $3.6 Million to Boost Prefilled Syringe Capabilities

The company officially launched new production suites, a revamp of its development labs, and more at its Thousand Oaks, Calif., cell therapy manufacturing facility.

Abzena Launches GMP Cell-Based Potency Testing in US and UK Sites, Boosting Analytical Capabilities

With this $3.6 million investment, the CDMO will strengthen its advanced labeling, automated visual inspection, and fill/finish technology.

Circio Forms Collaboration with Certest to Develop LNP Formulations

The company will now include GMP cell-based potency assays at its Cambridge, UK, and San Diego, Calif., sites expanding its early and late phase analytical capabilities.

BioPharmaSpec Launches Three New R&D Facilities in Europe

Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.

FDA Approves Kedrion's Bolognana Plant for Production of PLGD-1 Therapeutic

The new European facilities located in German, Italy, and Lithuania will specialize in drug discovery and R&D services.

Related Content

Fujifilm Completes Expansion of Cell Therapy Facility

With FDA's clearance, Kedrion can manufacture Ryplazim (plasminogen, human-tvmh), the first and only FDA-approved therapy for treating PLGD-1, at its Bolognana, Italy, site.

Pii Invests $3.6 Million to Boost Prefilled Syringe Capabilities

The company officially launched new production suites, a revamp of its development labs, and more at its Thousand Oaks, Calif., cell therapy manufacturing facility.

Abzena Launches GMP Cell-Based Potency Testing in US and UK Sites, Boosting Analytical Capabilities

With this $3.6 million investment, the CDMO will strengthen its advanced labeling, automated visual inspection, and fill/finish technology.

Circio Forms Collaboration with Certest to Develop LNP Formulations

The company will now include GMP cell-based potency assays at its Cambridge, UK, and San Diego, Calif., sites expanding its early and late phase analytical capabilities.

BioPharmaSpec Launches Three New R&D Facilities in Europe

Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.